Portland, Oregon-based EndoSound designed the EVS endoscopic ultrasound (EUS) device to attach to upper gastrointestinal endoscopes. It easily integrates to any endoscopy center’s existing ecosystem and provides access to both imaging and a therapeutic procedure.
EndoSound believes the EVS could shift the site of care to more efficient settings like ambulatory surgery centers (ASCs). In a news release, the company said labeled EVS as “poised to revolutionize the landscape of EUS). The system initially received FDA breakthrough device designation in 2021.
EVS addresses infections associated with difficult-to-clean endoscope elevators. The minimally invasive procedure performed with the system assesses the diseases of the gastrointestinal tract. It also extends to other nearby organs and tissues. Its high-frequency sound waves produce detailed images of the pancreas, liver and gallbladder.
“We are thrilled to receive 510(k) clearance for our EVS, a testament to the dedication and innovation of the entire EndoSound team. This milestone underscores our commitment to advancing medical technology and improving patient outcomes,” said Dr. Stephen Steinberg, EndoSound president and CEO. “With the EVS, we aim to not only enhance the safety of endoscopic procedures but also contribute to expanding access to care for patients worldwide.”
